Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of oral SAL0137 in adults with elevated cardiovascular risk and elevated lipoprotein(a)
CTR20262559Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0137 in lipoprotein(a) hyperlipoproteinemia (Lp(a)), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
SAL0137
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on CTR20262559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262559.